Novel oral agents for multiple sclerosis

被引：5
|
作者：
Burton, Jodie M. [1 ]
O'Connor, Paul [1 ]
机构：
[1] St Michaels Hosp, Div Neurol, Multiple Sclerosis Clin, Toronto, ON M5B 1W8, Canada
来源：
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS | 2007年 / 7卷 / 03期
关键词：
D O I：
10.1007/s11910-007-0034-2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In 1993, interferon beta-1b, the first clinically proven disease-modifying agent for multiple sclerosis, was approved, with several comparable agents following close behind. These agents have been beneficial in reducing relapse events and MRI lesions, but all require parenteral administration, leading some otherwise eligible patients to decline such therapies. Oral agents have been studied for decades with mixed results, but a small number of medications currently being tested in phase II/III clinical trials have shown promise in efficacy and tolerability. This review assesses the results of the more thoroughly studied of these agents, some of which may soon be approved for use in multiple sclerosis.
引用
收藏
页码：223 / 230
页数：8
相关论文
共 50 条
  • [11] Fingolimod: a novel oral immunomodulatory treatment for multiple sclerosis
    Javed, Adil
    Soliven, Betty
    FUTURE NEUROLOGY, 2011, 6 (03) : 315 - 325
  • [12] Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
    Sartori, Arianna
    Carle, Dawn
    Freedman, Mark S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1019 - 1027
  • [13] Risk of early relapse following switch to oral agents for multiple sclerosis
    Spelman, T.
    Mekhael, L.
    Burke, T.
    Butzkueven, H.
    Hodgkinson, S.
    Havrdova, E.
    Horakova, D.
    Duquette, P.
    Izquierdo, G.
    Grand'Maison, F.
    Grammond, P.
    Barnett, M.
    Lechner-Scott, J.
    Alroughani, R.
    Trojano, M.
    Lugaresi, A.
    Granella, F.
    Pucci, E.
    Vucic, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 270 - 271
  • [14] FACTORS ASSOCIATED WITH PRESCRIBING OF ORAL DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS
    Earla, J. R.
    Hutton, G. J.
    Thornton, J. D.
    Aparasu, R. R.
    VALUE IN HEALTH, 2019, 22 : S390 - S390
  • [15] Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis
    Nwankwo, Enyioma
    Allington, Douglas R.
    Rivey, Michael P.
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2012, 2 : 15 - 28
  • [16] Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies
    DeAngelis, Tracy
    Lublin, Fred
    MOUNT SINAI JOURNAL OF MEDICINE, 2008, 75 (02): : 157 - 167
  • [17] Novel biologic agents for multiple sclerosis and their impact on managed care
    Chao, SH
    Smith, CH
    FORMULARY, 2004, : 15 - 22
  • [18] Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents
    Girouard, Nathalie
    Soucy, Nanda
    PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 101 - 108
  • [19] Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOTHERAPY, 2023, 43 (06): : 473 - 484
  • [20] Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview
    Mulakayala, Naveen
    Rao, Pallavi
    Iqbal, Javed
    Bandichhor, Rakeshwar
    Oruganti, Srinivas
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 60 : 170 - 186
12345